Health Condition 1: L409- Psoriasis, unspecified
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patient with two or more of the following symptoms Scaling Erythema With or without itching Candle crease sign positive Dryness of skin Cracks followed by itching Auspitz sign positive Thickness
Exclusion criteria
Exclusion criteria: Psoriatic arthritis Eczema Psoriasis with evidence od any other skin disease Fungal infection Any other systemic disorder Lesion with secondary infection Epilepsy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efiicacy of the trial drug is measured by PASI score and improvement in the clinical condition is assured by reducing the degrees of involvement of the body region from 5 to 1Timepoint: 45 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in the remission of the disease and improvement in the qualitu of life in children Quality of life will be measured with standard published questionarieTimepoint: Before and after treament assessment in interval of 45 days | — |
Countries
India
Contacts
National institute of siddha